ALK has received Health Canada approval for Ragwitek (standardized allergen extract, short ragweed (ambrosia artemisiifolia sublingual tablet) for treating moderate-to-severe ragweed pollen allergies in children aged five and up.

The once-daily tablet’s approval stemmed in part from positive data from a phase 3, 1,022-participant trial of children and adolescents with ragweed allergic rhinitis and conjunctivitis, the largest study to date, according to the company.

The study found that Ragwitek significantly improved symptoms in patients aged five to 17 and decreased medication use compared to placebo, with a strong level of tolerance and a low level of discontinuation rates due to adverse events.